



Published in final edited form as:

*Neuroimage*. 2016 October 01; 139: 405–414. doi:10.1016/j.neuroimage.2016.06.044.

## A regularized full reference tissue model for PET neuroreceptor mapping

Joseph. B. Mandeville<sup>1</sup>, Christin Y.M. Sander<sup>1</sup>, Hsiao-Ying Wey<sup>1</sup>, Jacob M. Hooker<sup>1</sup>, Hanne D. Hansen<sup>2</sup>, Claus Svarer<sup>2</sup>, Gitte M. Knudsen<sup>2</sup>, and Bruce R. Rosen<sup>1</sup>

<sup>1</sup> Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA

<sup>2</sup> Neurobiology Research Unit, Rigshospitalet and University of Copenhagen, DK-2100 Copenhagen, Denmark

### Abstract

The full reference tissue model (FRTM) is a PET analysis framework that includes both free and specifically bound compartments within tissues, together with rate constants defining association and dissociation from the specifically bound compartment. The simplified reference tissue model (SRTM) assumes instantaneous exchange between tissue compartments, and this “1-tissue” approximation reduces the number of parameters and enables more robust mapping of non-displaceable binding potentials. Simulations based upon FRTM have shown that SRTM exhibits biases that are spatially dependent, because biases depend upon binding potentials. In this work, we describe a regularized model (rFRTM) that employs a global estimate of the dissociation rate constant from the specifically bound compartment ( $k_4$ ). The model provides an internal calibration for optimizing  $k_4$  through the reference-region outflow rate  $k_2'$ , a model parameter that should be a global constant but varies regionally in SRTM. Estimates of  $k_4$  by rFRTM are presented for four PET radioligands. We show that SRTM introduces bias in parameter estimates by assuming an infinite value for  $k_4$ , and that rFRTM ameliorates bias with an appropriate choice of  $k_4$ . Theoretical considerations and simulations demonstrate that rFRTM reduces bias in non-displaceable binding potentials. A two-parameter reduction of the model (rFRTM2) provides robust mapping at a voxel-wise level. With a structure similar to SRTM, the model is easily implemented and can be applied as a PET reference region analysis that reduces parameter bias without substantially altering parameter variance.

### Introduction

Reference tissue models (RTMs) have been developed and employed in PET analyses for over two decades. Under the assumption that a reference region in the brain is devoid of specific binding of PET radioligand, RTMs enable calculation of non-displaceable binding potentials ( $BP_{ND}$ ) in each brain voxel by comparing the tissue time-activity curve (TAC) to

---

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

the reference region, which serves as a surrogate of the plasma TAC while also providing an index of non-specific binding (Gunn et al., 2001, Slifstein and Laruelle, 2001). This approach obviates arterial blood sampling by providing a surrogate for plasma radioligand concentrations.

Various RTM approaches have been developed in the literature to address the balance between parameter variance and parameter bias. A full reference tissue model (FRTM) fits four parameters for each TAC (Cunningham et al., 1991, Lammertsma et al., 1996), which may represent a relatively noiseless brain region of interest (ROI) or a much noisier image voxel. The sensitivity of FRTM to noise motivated the simplified reference tissue model (SRTM), which reduces the number of model parameters to three (Lammertsma and Hume, 1996, Gunn et al., 1997). However, even SRTM lacks robustness to noise at the voxel-wise level, and so a two-parameter variant (SRTM2 or MRTM2) often is employed that uses a global value for the washout time constant in the reference region (Wu and Carson, 2002, Ichise et al., 2003). SRTM and SRTM2 have become standard PET analysis strategies and form the foundation of several extended methods that modify basis functions to describe dynamic changes in binding due to within-session functional challenges (Alpert et al., 2003, Zhou et al., 2006, Normandin et al., 2012).

SRTM is predicated upon an assumption of instantaneous equilibration between the free and bound compartments in all tissues. While this assumption is never strictly accurate, the model produces excellent fits to experimental data for many radioligands. Analyses of simulated data that conform to FRTM have found that SRTM generally provides relatively accurate estimation of  $BP_{ND}$ , with errors typically below 10% for selected radioligands when fitting a full 90-minute TAC (Slifstein et al., 2000, Salinas et al., 2015), as commonly done when using a compound labeled by  $^{11}\text{C}$ . Three-parameter variants of SRTM overestimate  $BP_{ND}$  in low-binding regions (Salinas et al., 2015) and exhibit a relatively high variance in the presence of noise (Wu and Carson, 2002). The model provides a separate estimate of the washout rate constant ( $k_2'$ ) in the reference region for each voxel or ROI, which motivated a reduced model that provides regularization by fixing the value of  $k_2'$  as a global parameter. However, many investigators have noted that different regions provide different values for this rate constant, and the method for defining a global value is not standardized; various reports have suggested using the value in a high binding region (Seneca et al., 2006), or the median or average across either the brain (Wu and Carson, 2002) or a series of ROIs (Ichise et al., 2003, Seo et al., 2015). In contrast to the three-parameter SRTM, the two-parameter variant generally underestimates  $BP_{ND}$  in low-binding regions (Schuitemaker et al., 2007), and bias in high-binding regions is smaller and depends upon a subjective choice for  $k_2'$ .

Though SRTM biases suggested by previous studies are not large for many radioligands, this level of accuracy is comparable with typical test-retest reproducibility (Cropley et al., 2008, Lee et al., 2013), suggesting that model error cannot be discounted as a source of variance even for studies of basal receptor concentrations. In occupancy studies that measure modulations of available receptors, model bias in  $BP_{ND}$  produces bias in estimates of occupancy. In displacement studies using either a drug or tasks that modulate neurotransmitter levels, a 10% error can be significant, because changes in true occupancy

can be subtle when using behavioral tasks or low drug doses. Following administration of large agonist challenges, some PET radioligands exhibit little or no change in apparent occupancy, or even paradoxical increases in binding potential (Laruelle, 2000). Behavioral tasks that attempt to detect changes in dopamine efflux using [ $^{11}\text{C}$ ]raclopride have reported positive or negative changes in  $BP_{ND}$  below 10% (Zald et al., 2004, Hakyemez et al., 2008, Martin-Soelch et al., 2011), a regime where model error can play a major role in drawing scientific inferences.

The goal of this work was to develop a reference tissue model that reduces parameter bias relative to SRTM without substantially altering parameter variance. Our search for an alternative model began with the observation that SRTM2 analyses of occupancies often exhibit a characteristic spatial pattern in the limit of low displacement, with apparent displacement in the highest binding regions and apparent paradoxical increases in  $BP_{ND}$  in surrounding low-binding regions. These patterns are most evident in multi-session averages or spatially smoothed data and suggest a source of bias in these studies that varies monotonically with  $BP_{ND}$ . To devise an alternative model to SRTM, we developed a basis-function approach to FRTM, and we regularize the model by employing a global estimate for the dissociation rate constant from the specifically bound compartment. SRTM is one solution to the model in the limit of infinite  $k_4$ , but this solution imparts a bias in the estimate of model parameters relative to FRTM. We describe a method to empirically estimate a global value of  $k_4$  to minimize parameter bias, and we employ simulations to demonstrate that our method reduces bias in the estimation of  $BP_{ND}$  and receptor occupancies.

## Methods

Fig. 1a shows FRTM and the reduction of the model to SRTM. Both models assume that the reference region exhibits one-compartment kinetics representing non-displaceable PET radioligand that is either free or non-specifically bound. FRTM models the target region as a compartmental summation of non-displaceable and specific binding (Gunn et al., 2001), whereas SRTM assumes “1-tissue” kinetics in the limit of fast exchange between free and bound compartments. Eq. A1 presents the differential equations describing FRTM.

### Regularized FRTM (rFRTM)

Eq. A6 provides an exact expression for FRTM in a form designed to mimic the basis-function approach to SRTM. To derive this formula, we replaced the SRTM approximation of instantaneous equilibrium with an expression (Eq. A3) relating the time dependence of the bound concentration to the total tissue concentration and its derivative. In this way, we model the true bound fraction in the tissue as a function of time. The FRTM model has four parameters, including two rate constants ( $k_2$ ,  $k_4$ ), a ratio of rate constants ( $R_1 = k_2/k_2'$ ), and a parameter that depends upon  $BP_{ND}$  ( $k_{2a} = k_2/(1 + BP_{ND})$ ). The model incorporates convolution by an exponential equilibration function  $E(t) = \exp(-k_4(1 + BP_{ND})t)$  to account for non-equilibrium conditions that are reflected by a change in the tissue concentration.

$$C_T = R_1 C_R + k_2 \int (C_R - \dot{C}_T \otimes E) - k_{2a} \int (C_T - \dot{C}_T \otimes E) \quad [1]$$

The solution to this equation previously has been approached two different ways. The literature approach to FRTM attempts to derive all four parameters for each voxel or ROI, a strategy that is limited by convergence problems, high parameter variance, and long computational times (Lammertsma et al., 1996, Slifstein and Laruelle, 2001). As an alternative to FRTM, SRTM employs the approximation that  $k_3$  and  $k_4$  approach infinity (equivalently, the time constants  $1/k_3$  and  $1/k_4$  approach zero) in order to reduce the number of parameters from four to three and produce an equation that is linear in all parameters. In this limit, the convolution terms vanish. This approach reduces parameter variance (Lammertsma and Hume, 1996) but introduces bias in parameter estimates by failing to accurately model the specifically bound fraction of the tissue radioligand concentration. Bias will be more pronounced for slower radioligands (smaller  $k_4$ ) and for low-binding regions (smaller  $BP_{ND}$ ), because the effective rate for equilibration to a steady state in Eq. 1 is  $k_4(1 + BP_{ND})$ .

We propose a new approach (rFRTM) using a globally constant value of  $k_4$  that is selected in order to minimize regional bias in  $k_2'$ . We show below that  $k_2'$ , which should take the same value irrespective of the tissue region under analysis, cannot be regionally invariant in SRTM when association and dissociation rates constants are finite. Within the context of FRTM, bias reduction in  $k_2'$  is accompanied by bias reduction in  $BP_{ND}$ , which is the main parameter of interest.

### Solution of rFRTM: Overview

Application of the proposed model requires two steps: 1) a method to solve Eq. 1 provided that the best global value for  $k_4$  is known, and 2) a method to determine the best global value for  $k_4$ . Although these steps could be combined in principle by simultaneously fitting many voxels or regions of interest, we employed a procedure in which the model first was applied multiple times in a region-of-interest analysis using different values of global  $k_4$  in each analysis, and subsequently the best value of  $k_4$  was identified and used for a final analysis of all regions and voxels. The steps for solving Eq. 1 and identifying the best global  $k_4$  are described in the following two sections.

### Solution of rFRTM for individual TACs

Given an *a priori* estimate of the global value for  $k_4$ , Eq. 1 can be solved either by non-linear fitting or by an iterative approach that incorporates repeated application of a linear model; our approach used the latter method. To avoid using the relatively noisy convolution term in basis functions, our implementation rearranged Eq. 1 to add the convolution integral to the dependent variable.

$$C_T + \left( k_2^{(i-1)} - k_{2a}^{(i-1)} \right) \int \dot{C}_T \otimes E^{(i-1)} = R_1^{(i)} C_R + k_2^{(i)} \int C_R - k_{2a}^{(i)} \int C_T \quad [2]$$

Specifically, we used the following steps to solve Eq. 2.

1. Create three basis functions with “n” time points for  $C_R$ ,  $\int C_R$ , and  $\int C_T$ . These basis functions form a 3-by-n design matrix X. Using an n-by-n diagonal weighting function W to represent the time-changing magnitude of signal variance, compute the 3-by-n matrix  $M = (X^T W^{-1} X)^{-1} X^T W^{-1}$  for use in all iterations. Initialize parameters by SRTM using the weighted least squares estimate  $\beta = M C_T$ , where the vector  $\beta = [R_1 \ k_2 \ k_{2a}]$ .
2. Compute  $BP_{ND} = k_2 / k_{2a} - 1$  using parameter estimates from the previous iteration. Compute the convolution of the tissue derivative with  $E(t) = \exp(-k_4^{global} (1 + BP_{ND}) t)$  for each time point, where  $k_4^{global}$  is a fixed value used for all iterations and all regions. Create a modified tissue vector ( $C_T'$ ) equal to the left hand side of Eq. 2. Update parameter values as  $\beta = M C_T'$ .
3. Repeat step #2 until a stopping criterion is reached: 1) the change in  $BP_{ND}$  does not exceed some predefined tolerance, 2) the number of iterations exceeds some predefined limit, 3) or  $BP_{ND}$  is negative.

Intuitively, this formulation can be viewed as a model that estimates the tissue concentration profile that would be required to conform to SRTM by adding a correction to the dependent variable to account for overestimation of the bound fraction due to the SRTM approximation of instantaneous equilibrium. Relative to modification of basis functions as suggested by Eq. 1, or alternatively a non-linear fitting approach, this strategy has the additional advantage of simplicity and speed because it proceeds by repeated application of the same linear model for all iterations.

### Estimation of global $k_4$ using post hoc analysis

Implementation of rFRTM requires a global value  $k_4$ , and this parameter can be estimated from a *post hoc* analysis of regional trends in a derived parameter, the reference-region washout rate constant ( $k_2' = k_2 / R_1$ ). Although  $k_2'$  is evaluated repeatedly for every voxel or region of interest, it should take the same value irrespective of the region under analysis. However,  $k_2$  cannot in general be the same for both rFRTM and SRTM because it multiplies different basis functions in each model. If rFRTM represents ground truth and the value of  $k_4$  is finite and global, then SRTM biases the  $k_2$  basis function by ignoring the convolution term. Under these conditions, SRTM biases both  $k_2$  and  $k_2'$ , particularly at low values of  $BP_{ND}$  where the convolution term becomes larger. More generally, values of  $k_2'$  and  $BP_{ND}$  derived from rFRTM will be biased with dependencies upon the local binding potential through the convolution term unless the value of  $k_4$  assumed in analysis matches the true value. Within the context of rFRTM, reducing bias in  $k_2'$  is equivalent to reducing bias in  $BP_{ND}$ , because an inaccurate estimate of  $k_4$  biases both parameters through the convolution term. This claim is evident from Eq. 1 and also is demonstrated in simulations in this report.

In this work, we estimated  $k_4^{global}$  as the value that minimized the dependence of  $k_2'$  upon  $BP_{ND}$ . After defining a series of regions with different values of  $BP_{ND}$ , we performed a series of analyses on these regions with a different value of  $k_4^{global}$  used in each analysis. This

process generates Q different relationships between  $k_2^{(qr)}$  and  $BP_{ND}^{(qr)}$  across the R regions. Rather than perform a purely graphical analysis to determine the value of  $k_4^{global}$  that minimizes the dependence  $k_2'$  upon  $BP_{ND}$ , we automated analysis using two different methods that produced very similar results: 1) minimize the mean squared error between  $k_2'$  and the average value of  $k_2'$  using a grid search for  $k_4^{global}$ , or 2) employ an approximate functional form to simultaneously fit all curves of  $k_2'$  versus  $BP_{ND}$  for a series of stepped values for  $k_4^{global}$ . For the latter method, we employed an ad hoc functionality designed to satisfy these criteria within the framework of rFRTM:

1.  $k_2'$  should become independent of  $BP_{ND}$  when  $k_4^{(q)}$  matches the optimal value (denoted  $k_4^{global}$ ), because then the model matches the assumed ground truth. The sign of bias in  $k_2'$  should depend upon the relative magnitude of  $k_4^{(q)}$  in relation to  $k_4^{global}$ , because the sign of bias depends upon the magnitude of the convolution term.
2. Higher values of  $BP_{ND}$  should be associated with less biased values of  $k_2'$ , because the convolution term tends toward zero in high-binding regions (i.e., SRTM becomes a more accurate approximation).

According to these principles, we fit the dependencies of  $k_2'$  on  $BP_{ND}$  for all Q values of  $k_4^{(q)}$  as a constant value plus a decreasing exponential function that introduces bias with a sign dependent upon the relative magnitude of  $k_4^{global}$  and  $k_4^{(q)}$ . For convenience, we employed time constants ( $1/k_2'$  and  $1/k_4$ ) rather than rate constants in the fit:

$$1/k_2^{qr} = 1/k_2^{global} + A \left( 1/k_4^{global} - 1/k_4^q \right) \exp \left( - (R_0 + R_1/k_4^q) BP_{ND}^{qr} \right) \quad [3]$$

The parameters of interest in this fit are the two global rate constants ( $k_2^{global}$ ,  $k_4^{global}$ ). This functionality produces an approximate form across a wide range of values for  $k_4^{(q)}$ .

### Reduction to rFRTM2

Ultimately, the goal of rFRTM is to enable accurate parameter mapping at a voxel-wise level, and so further regularization is required. Specifically, the goal is to fix two global parameters ( $k_4^{global}$ ,  $k_2^{global}$ ) in order to reduce the model to the same two local parameters used for SRTM2 ( $k_2$ ,  $k_{2a}$ ). Fixing  $k_2'$  in SRTM2 changes the structure of model bias, because  $k_2'$  is not invariant in SRTM. Conversely, rFRTM2 should maintain accuracy while reducing parameter variance, provided that we can accurately identify the value of  $k_4^{global}$  that produces invariance in  $k_2'$ . The two-parameter reduction of rFRTM2 follows the same strategy used to reduce SRTM2 to two parameters and two basis functions (Ichise et al., 2003).

$$C_T = k_2 \left( \frac{C_R}{k_2^{global}} + \int (C_R - \dot{C}_T \otimes E) \right) - k_{2a} \int (C_T - \dot{C}_T \otimes E). \quad [4]$$

Note that solution of rFRTM2 follows an approach similar to the one described by Eq. 2 for the 3-parameter implementation of rFRTM. Also, these models need modification to describe a functional challenge, as in a drug occupancy study or a behavioral study using a single synthesis of a radioligand such as raclopride. Such paradigms can be analyzed by applying a temporal dependence to the  $k_{2a}$  parameter (Alpert et al., 2003, Zhou et al., 2006), so that values of  $k_{2a}$  after the functional challenge are associated with a change in  $BP$ . To compute changes in occupancy for the simulated data in this report, we use this same strategy such that  $k_{2a} \rightarrow k_{2a} + k_{2a} f(t)$ , where  $f(t)$  in this report is modeled as a rapid change to a new state using a sigmoidal “step function” beginning at time  $t_0$  with  $f(t') = t' / \text{sqr}(1 + t'^2)$  and  $t' = (t - t_0)/\tau$ , where the time constant ( $\tau$ ) was set to a value of 1 min.

### Forward-model Simulations

Simulations were used to confirm predictions of theory and to determine bias and variance properties of kinetic models. Simulations within the framework of FRTM tested these hypotheses: 1) An inaccurate estimate of  $k_4$  biases both  $k_2'$  and  $BP_{ND}$ , and reducing bias in  $k_2'$  is equivalent to reducing bias in  $BP_{ND}$ ; 2) in the presence of noise, analyses based upon SRTM and rFRTM produce similar variances in estimates of  $BP_{ND}$ , and analyses based upon SRTM2 and rFRTM2 produce similar variances that are lower than the 3-parameter versions of these models; 3) due to bias introduced into  $BP_{ND}$ , estimates of occupancy using within-scan challenges are biased in SRTM and SRTM2, and biases can be mitigated using rFRTM.

Forward-model simulations with and without noise employed the system of differential equations in Eq. A1 to iteratively compute profiles of PET radioligand concentration versus time for selected experimental conditions. Simulations focused on two commonly used radioligands of dopamine receptors that often employ SRTM for analysis. [ $^{11}\text{C}$ ]NNC-112 targets  $D_1$  receptors and can detect extra-striatal binding, which emphasizes the need to accurately model binding parameter across a wide range of binding potentials. [ $^{11}\text{C}$ ]Raclopride is a  $D_2/D_3$  selective ligand that is widely used in applications that characterize changes in basal ganglia dopamine levels in response to behavioral cues or other stimuli. For each of Figures 2-4, input parameters for simulations are shown in Table 1. The temporal shape and magnitude of plasma concentrations were adjusted to roughly match experimentally measured reference-region TACs from the cerebellum of non-human primates (NHP) using the forward model specified by Eq. A1. Occupancy maps in Figure 4 were simulated as instantaneous reductions in  $k_3$  that were localized to the right nucleus accumbens and occurred at 40 minutes into the scan.

Data presented in Figures 3d and 4 included a standard model of synthetic noise in which signal variance is proportional to signal multiplied by an exponentially increasing decay correction (Logan et al., 2001); for the uniform time bins used in simulations, noise was modeled as  $\sigma = \sqrt{S \cdot C \cdot e^{\lambda t}}$ , where  $C$  is the time-dependent concentration of radioligand,  $\lambda$

is the rate of radioactive decay, and  $S$  is a scale factor specifying the level of noise. For Figure 3d, the reference-region curve was assumed to have a relatively low level of noise ( $S=2$  Bq/cc), and the level of noise in tissue regions was increased from zero to a large value ( $S=200$  Bq/cc) that corresponded to a fractional standard deviation in the TAC of about 35% at 90 minutes. For each level of noise, 50,000 TACs were generated to define standard deviations in estimates of  $BP_{ND}$ .

### Experimental NHP Data

Data were collected in NHP in order to demonstrate that 1) the dependence of  $k_2'$  on  $BP_{ND}$  is consistent with the proposed model, and  $k_2'$  becomes invariant with an appropriate global choice of  $k_4$ ; 2) the spatial relationship between  $BP_{ND}$  values suggested by SRTM and rFRTM is consistent with simulations; 3) the proposed rFRTM method produces robust voxel-wise maps. All NHP experimental procedures complied with the regulations of the Subcommittee on Research Animal Care at Massachusetts General Hospital. Data were collected from anesthetized NHP using simultaneous PET/fMRI according to methods described previously (Mandeville et al., 2013, Sander et al., 2013, Sander et al., 2015).

### Analysis of Simulations and NHP Data

Analyses of simulated and real data employed SRTM, SRTM2, rFRTM, or rFRTM2. Parameters were solved by weighted least squares assuming a noise-free approximation to Poisson weights (Thiele and Buchert, 2008), with convergence for rFRTM and rFRTM2 defined to be a change in  $BP_{ND}$  less than 0.1%. Analyses of simulated occupancy incorporated a sigmoidal regressor to model a change in the parameter  $k_{2a}$  (Alpert et al., 2003, Zhou et al., 2006). To define the value of  $k_4$  to use in rFRTM analyses, analyses of  $k_2'$  versus  $BP_{ND}$  were fit using Eq. 3. When describing simulation results, we denote true binding potentials as  $BP$ , defined as the ratio of  $k_3$  to  $k_4$  values that were used as inputs for the forward-model simulations, and  $BP_{ND}$  is a derived quantity from analyses of data. Within simulations, bias in  $BP_{ND}$  was assessed as a percentage relative to the known value of  $k_3/k_4$ .

All NHP data were aligned to the INIA19 rhesus macaque brain atlas (Rohlfing et al., 2012) using T1-weighted MRI data, and the known transformation between PET and MRI defined the atlas-based region for the right nucleus accumbens (cyan region, Fig. 4b) in a manner that was spatially consistent with the PET  $BP_{ND}$  map (colored image, Fig. 4b). To define a set of regions that varied systemically versus  $BP_{ND}$ , NHP data were analyzed initially by SRTM2 to generate a map of  $BP_{ND}$ . Brain voxels then were sorted by  $BP_{ND}$  values so that they could be efficiently grouped into less noisy ROIs for further analyses based upon  $BP_{ND}$  similarity. To minimize bias from noise in low-binding regions, ROIs were excluded below a  $BP_{ND}$  threshold, which generally was set to 1 or 2. ROIs were analyzed by rFRTM using five values for  $k_4$ , and all data were then fit by Eq. 3 to define the global value of  $k_4$  to use in a final analysis.



## Results

Figure 2 provides an intuitive window into assumptions underlying SRTM and rFRTM and how these assumptions bias measurements of  $BP_{ND}$ . Noiseless simulated time-activity curves for a reference region and a target region are shown in Fig. 2a for a relatively low-binding region ( $BP=1$ ) using a PET radioligand that has an offset time constant from the bound compartment of  $1/k_4 = 15$  min. Fig. 2b compares the true fraction of the target tissue concentration that is specifically bound (black points) versus values assumed by SRTM (red line) and by rFRTM using different analysis values for  $1/k_4$ . The bound radioligand fraction does not reach the SRTM approximation until about 30 minutes into the scan, and SRTM also does not match the true value at the end of the scan. Because the goal of reference models is to estimate specifically bound tissue fractions in order to define  $BP_{ND}$ , inaccurate estimates of  $k_4$  produce bias in  $BP_{ND}$ . When the analysis value of  $k_4$  matches the true value, the analytical estimate for the bound fraction (Eq. A3) matches the simulated value.

Figures 3a and 3b demonstrate that an inaccurate estimate of  $k_4$  used in analysis introduces bias into both  $k_2'$  and  $BP_{ND}$ , and that this bias is a function of  $BP$ . An assumption of instantaneous equilibrium (SRTM, red curves) causes positive bias in both  $BP_{ND}$  and the time constant  $1/k_2'$ . Conversely, both parameters exhibit negative bias when kinetics are assumed be slower than reality (blue and purple curves). The derived parameter  $k_2'$  becomes an invariant quantity only when the value of  $k_4$  used in rFRTM analysis matches the true value used for the forward-model simulation. Note that Fig. 3a provides a graphical motivation for the fitting method of Eq. 3.

When SRTM2 employs a global value for  $k_2'$ , bias in  $BP_{ND}$  is similar in magnitude to SRTM, as shown in Fig. 3c. If one defines  $k_2'$  to be the projected asymptotic value in the limit of high  $BP$  (long dashes), then SRTM2 (red) underestimates  $BP_{ND}$  at all values of  $BP$ . However, literature methods define the value of  $k_2'$  for SRTM2 using analyses of regions with a finite  $BP_{ND}$  (Wu and Carson, 2002, Ichise et al., 2003); in this case, SRTM2 will produce a positive bias in the highest-binding regions and a negative bias in low-binding regions (short dashes). Conversely, rFRTM2 (black) shows very little residual bias (long dashes) when Eq. 3 identifies global values of  $k_4$  and  $k_2'$ . Additionally, the figure depicts the effect an incorrect value of  $k_2'$  at the correct value of  $k_4$  (black curve, short dashes). Because rFRTM2 has a model structure similar to SRTM2, it exhibits a similar sensitivity to errors in  $k_2'$ .

Parameter bias is not the only criteria for selecting PET kinetic models; parameter variance is another important quantity. Fig. 3d compares percentage standard deviations in estimates of  $BP_{ND}$  at different noise levels. SRTM2 is used as the reference, and so the SRTM2 curve in the figure is the line of identity. As expected, SRTM2 exhibits small variance in  $BP_{ND}$  relative to SRTM. rFRTM2 and SRTM2 have similarly noise sensitivities that are small compared to the three-parameter models.

Inaccuracies in SRTM become problematic in the context of functional studies that attempt to characterize small changes in receptor occupancy; in particular, spatial variations in binding potentials can potentially bias inferences about changes in occupancy. Figure 4a

reports analyses of simulated data for a radioligand like [ $^{11}\text{C}$ ]raclopride. SRTM exhibits a positive bias in occupancy (solid red line, Fig. 4a), while SRTM2 (dashed lines) shows a strong monotonic dependence of occupancy on  $BP$  with bias dependent upon the global value for  $1/k_2'$ , which was chosen to be 3.8 min from a high-binding region ( $BP=6$ ) for the long dashed line or 4.4 min from a lower binding region ( $BP=4$ ). Bias in occupancy for rFRTM was reduced to a few percent using Eq. 3 to estimate the value of  $k_4$  (black line).

Results of Fig. 4a suggest that spatial variations in  $BP$  will yield occupancy values with a regional bias, and other panels in Fig. 4 illustrate the potential for reference tissue approaches to exhibit spatial variations in bias that produce false positive results or mask real changes in occupancy. A simulated 10% change in occupancy was localized to the right nucleus accumbens (cyan region, Fig. 4b), with the magnitude of noise in each voxel illustrated by the TACs in Fig. 4b. Analysis of these data by SRTM suggested an increase in occupancy throughout basal ganglia, albeit with high noise in the map due to the inherent instability of three-parameter fits (Fig. 4c). Maps produced by SRTM2 showed a characteristic pattern of apparent positive changes in occupancy in the highest-binding regions surrounded by apparent decreases (Fig. 4c, top right). This pattern was altered either by choosing a different global value of  $k_2'$  or by changing the infusion paradigm; a bolus plus continuous infusion (BI) simulation designed to achieve a steady-state just prior to the challenge showed a different regional pattern of bias (Fig. 4c, bottom right). Conversely, using the fitting method of Eq. 3 to calibrate rFRTM, a change of about the correct magnitude was observed in the correct location with little bias in other areas of basal ganglia (Fig. 4c, bottom left), and this pattern was maintained for either a bolus or a BI injection of radioligand (not shown). Note that the cyan oval curves in these figures demarcate the lateralized change in simulated occupancy, and other apparent changes in binding potential are artifacts of analysis.

If rFRTM provides a realistic biological model, then application of rFRTM to experimental data should identify and remove correlations between  $k_2'$  and  $BP_{ND}$  that arise in SRTM, in agreement with the simulated data of Fig. 3a. Figure 5 applies rFRTM analyses to representative experimental data collected in anesthetized NHP using four different radioligands. Points in Fig. 5 represent analyses of ROIs created by grouping voxels with similar  $BP_{ND}$  values from a first-pass analysis. Each set of differently colored points in a figure panel represent an analysis using a different global value of  $k_4$ . As the analysis time constant  $1/k_4$  increases from 0 (SRTM, red) to larger values, curves first become flatter until the curvature reverses at low values of  $BP_{ND}$ . The best value of  $k_4$  to use in a final rFRTM analysis is the one that produces invariance of  $k_2'$ . Lines in Fig. 5 illustrate application of Eq. 3 to simultaneously fit all the data points for all values of  $k_4$ . Optimal values of global  $1/k_4$  estimated by the fit for these specific experiments were 10.4, 10.6, 11.6, and 56 min for the scans using [ $^{11}\text{C}$ ]raclopride, [ $^{11}\text{C}$ ]AZ-10419369, [ $^{11}\text{C}$ ]NNC-112, and [ $^{18}\text{F}$ ]fallypride, respectively. In eight repeated measurement in a single NHP using [ $^{11}\text{C}$ ]raclopride, estimates were reproducible with values of  $1/k_4=9.7 \pm 1.0$  min (mean  $\pm$  st. dev.).

Figure 6 demonstrates ROI and voxel-wise fits of the rFRTM to NHP data using [ $^{11}\text{C}$ ]NNC-112. Fig. 6a compares the two terms on the left-hand side of Eq. 2 in order to demonstrate that the convolution term, which is missing in SRTM, has much less noise than

the tissue concentration in a single voxel. Analysis of bilateral putamen by SRTM yields an excellent fit to data (Fig. 3b, gray curve and points), and rFRTM produces a fit of similar quality to the “corrected” data of Eq. 2 (black curve and points). SRTM reports a  $BP_{ND}$  value that is 9% higher than rFRTM in this region. The SRTM value for  $R_I$  is 15% lower than for rFRTM, consistent with the expectation that SRTM underestimates  $R_I$  values (Muzic and Christian, 2006, Thiele and Buchert, 2008).

Simulations suggest the rFRTM should enable robust voxel-wise mapping with parameter variance similar to SRTM, and Fig. 6c shows a map of  $BP_{ND}$  obtained with rFRTM2 in order to illustrate this point. Additionally, relative  $BP_{ND}$  magnitudes obtained by rFRTM2 and SRTM2 are compared as a ratio in Fig. 6d using a percent deviation map, with the blue-green color scale indicating lower  $BP_{ND}$  values for SRTM2 relative to rFRTM2. The map generated by SRTM2 used a global value for  $k_2'$  from putamen following the method that suggests obtaining this value from a high-binding region (Seneca et al., 2006). The selected value ( $1/k_2'=15.5$  min) was higher than the asymptotic value of 14.3 min in Fig. 5c, and so the simulations of Fig. 3c suggest that SRTM2 should underestimate  $BP_{ND}$  in low-binding regions but overestimate  $BP_{ND}$  in the highest-binding regions. The map demonstrates the expected relationship between the two methods and is consistent with simulations.

Voxel-wise analyses using a linear-model formulation of rFRTM2 (Eq. 2) reached convergence in most brain areas after about 5-10 iterations using a 0.1% tolerance on  $BP_{ND}$ , and accordingly the processing time surpassed a linear-model implementation of SRTM2 by a factor of about 5-10. For a typical NHP dataset with 95 frames and 350,000 voxels, processing time increased from 2.5 min using SRTM2 to 15 min using rFRTM2. Relaxing the tolerance will reduce the number of required iterations and the computational time. The iterative linear-model implementation of rFRTM2 converged much faster than non-linear damped least-squares minimization using a Levenberg-Marquardt algorithm, which increased computation time by a factor of about 100 over linear model iteration.

## Discussion

SRTM has become a common PET analysis strategy for reversible radioligands that can be appropriately analyzed by reference region methods, and this method has a number of distinct advantages, including deterministic solutions and simple implementation. For many applications that map receptor densities or investigate pharmacological challenges that produce large changes in receptor occupancy, SRTM offers sufficient accuracy while also guarding against instabilities and potentially larger errors that can arise in more complicated models. For ROI analyses, the three-parameter SRTM requires no subjective parameter estimates and generally produces small bias in the highest-binding regions. The two-parameter SRTM2 requires a subjective assignment of one global parameter ( $k_2'$ ) but increases robustness to noise while offering a level of bias comparable to SRTM. As testament to the popularity of SRTM, two early papers describing the method (Lammertsma and Hume, 1996, Gunn et al., 1997) have garnered about one thousand citations over the past decade (see (Salinas et al., 2015)).

Based upon simulations that assumed a finite rate for  $k_4$  that was consistent with literature estimates (Farde et al., 1989, Pappata et al., 2002), we showed that biases inherent to SRTM can obscure detection of subtle changes in  $BP_{ND}$ , as illustrated by the inability of SRTM-based analyses to accurately identify the simulated  $BP_{ND}$  changes of Fig. 4. Spatially varying patterns of SRTM bias make interpretation difficult even if using a fast radioligand like raclopride. Using SRTM2, estimates of occupancy will vary depending upon a subjective selection of the reference region  $k_2'$  value, which is not globally invariant in that model. Moreover, the degree of apparent occupancy can change dramatically with the size of an ROI, due to spatial variations in bias. In general, both SRTM and SRTM2 exhibit a positive bias in estimates of occupancy in high-binding regions (e.g., Fig. 4), and so analyses based upon these models can produce false positive results.

In order to reduce bias due to model topology using a RTM approach, the SRTM approximation of instantaneous equilibrium must be abandoned, a step that requires inferences about rate constants associated with the specifically bound compartment. Prior versions of FRTM have employed a methodology that attempts to fit four parameters for each voxel or ROI (Lammertsma et al., 1996). PET analyses rarely use this approach, and it is impractical for voxel-wise mapping for several reasons. High-binding regions have little intrinsic sensitivity to the absolute values of  $k_3$  or  $k_4$ , as illustrated by the convergence of curves in Fig. 3a, whereas low-binding regions have limited sensitivity to specific binding parameters in the presence of noise. Fitting a simple TAC becomes unstable with four parameters, as the two local parameters used in SRTM2 generally are sufficient for good fits. Relative to FRTM as used in the literature, SRTM reduces parameter variance at the expense of increased parameter bias.

The model proposed here (rFRTM) offers an alternative to SRTM-based approaches, with the potential to ameliorate parameter bias without substantially altering parameter variance. In fact, SRTM is really just one solution of rFRTM in which the offset time constant is assumed to be zero, as illustrated by Fig. 3. rFRTM2 fits the same two local parameters as SRTM2, but it first requires a step of model identification to select optimal global values for  $k_2'$  and  $k_4$ . The former parameter is a property of the reference region that is fit repeatedly for each TAC, a process that conveniently provides a method to calibrate the model by selecting a value of  $k_4$  that produces invariance in  $k_2'$ . As shown by simulations within the FRTM model, bias reduction in  $k_2'$  is accompanied by bias reduction in estimates of  $BP_{ND}$  and occupancy.

One of the features of rFRTM is the ability to determine a value for  $k_4$  using a large portion of data, and our expectation is that estimates provided by this method will exhibit reduced variability relative to existing literature methods that obtain a value from each kinetic analysis. Using rFRTM, our results for  $k_4$  generally compare well to literature results subject to the limitations of large error bars in the literature and relatively few results reported here in anesthetize NHP. For [ $^{11}\text{C}$ ]raclopride, two different kinetic approaches estimated  $1/k_4$  values in the range 9 to 15 minutes in human subjects (Farde et al., 1989), which are comparable to our result. Our estimate for [ $^{11}\text{C}$ ]AZ-10419369 falls within a reported range of 0 to 16 minutes (Varnas et al., 2011). A human study reported values of 18 to 50 min for [ $^{11}\text{C}$ ]NNC-112. The large  $1/k_4$  value of nearly one hour for [ $^{18}\text{F}$ ]fallypride in

our NHP study is consistent with the long scan duration required to obtain reliable estimates of  $BP_{ND}$  using this tracer in humans (Vernaleken et al., 2011).

There is scant literature on the magnitude of *in vivo* biological variations in  $k_4$  across brain regions, subjects, or physiological states. If this rFRTM approach proves to increase precision in estimates of this parameter, even though estimates are global, it might serve an important function by providing *in vivo* estimates of shifts in the dissociation rate constant, which might differ across subject populations, in response to allosteric modulators (Wootten et al., 2013), or as a consequence of agonist-induced internalization, which has long been suspected as a source of confound in the interpretation of PET occupancies (Chugani et al., 1988, Laruelle, 2000, Ginovart, 2005).

### Potential Limitations

Compared to FRTM, which attempts to determine a value for  $k_4$  from each TAC, a potential criticism of rFRTM is that  $k_4$  might not be regionally invariant. However, rFRTM is predicated upon the assumption that the best average value of  $k_4$  can be identified even in the presence of local variations. Experimental data conform to this assumption (Fig. 5) by enabling identification of self-consistent models with invariant values of  $k_2'$  at some selected value for the average offset time constant from the bound compartment. Conversely, using simulations it is easy to show that attempts to estimate  $k_4$  directly from TACs using FRTM can succeed in the absence of noise but will produce severely biased results with even modest amount of noise, and bias becomes particularly pronounced at high values of  $BP_{ND}$  where FRTM becomes insensitive to  $k_4$ . The inability of FRTM to accurately determine local values for  $k_4$  limits our ability to address the appropriateness of using a global average value for this parameter.

The proposed method for estimating the global value of  $k_4$  requires a range of  $BP_{ND}$  values and a threshold on  $BP_{ND}$  to reduce noise-induced variations in  $k_2'$  and  $BP_{ND}$  that arise at low  $BP_{ND}$ . Ligands like [ $^{11}\text{C}$ ]NNC-112 and [ $^{18}\text{F}$ ]fallypride have striatal and extra-striatal binding to generate a wide distribution of  $BP_{ND}$  values using relatively large ROIs, which simplifies the identification of rate constants. Conversely, [ $^{11}\text{C}$ ]AZ-10419369 generally has  $BP_{ND}$  values below 2, which makes identification of  $k_4$  more difficult. This issue could limit applications of the model using very low-binding radioligands. Alternatively, the model could be employed using a fixed value of  $k_4$  for a given radioligand, just as SRTM uses a value of  $1/k_4=0$ , with similar methods employed for choosing  $k_2'$  for voxel-wise mapping.

The specific fitting method we employed in this study for estimating the best global value of  $k_4$  (Eq. 3) was designed to accomplish the more general goal of producing invariance in the parameter  $k_2'$ , but other approaches might accomplish the same end with equal or better accuracy. For instance, global  $k_4$  can be selected as the value that minimizes the slope of a simple linear fit of  $k_2'$  versus  $BP_{ND}$  across regions. Alternative approaches, including methods that obviate the need for a threshold on  $BP_{ND}$ , are subjects for continued research.

Achieving a level of accuracy better than 10% in  $BP_{ND}$  or occupancy is challenging, and this study addresses only one source of bias. A recent report discussed other SRTM biases associated with an imperfect reference region, mismatched distribution volumes between

reference and target regions, and the failure of reference models to account for blood volume contributions (Salinas et al., 2015). Other sources of bias in  $BP_{ND}$  include time-dependent errors that can arise from image reconstruction, attenuation correction, or radioactive metabolites. Occupancy studies in principle could be affected by modulation of cerebral blood flow and volume, effects that can be addressed experimentally using simultaneous fMRI to measure CBF or CBV during PET (Sander et al., 2014).

Finally, it is important to note that we did not investigate all possible variations of SRTM or other alternative approaches to estimating binding potentials or changes in occupancy. For instance, a study that attempts to measure dopamine release from a within-scan behavioral challenge using a bolus plus continuous infusion of [ $^{11}\text{C}$ ]raclopride might ignore much of the data prior to the challenge to avoid bias from early time points in a weighted-least squares SRTM analysis; this strategy presumably will reduce bias but also sacrifice detection power. While other potential approaches and contributions to parameter bias warrant further study, the SRTM “1-tissue” approximation can be addressed directly with this proposed model.

## Conclusions

In conclusion, we described a regularized FRTM approach for analysis of PET binding potentials and changes in occupancy. We demonstrated that the model can be calibrated using invariance in the reference-region outflow rate as an internal standard, and that mapping using the two-parameter rFRTM2 produces robust voxel-wise parameter estimates. Simulations and underlying principles suggest an improved level of accuracy of rFRTM relative to SRTM, without an increase in parameter variance. The main applications of this model are likely to be in functional studies that investigate small changes in occupancy, and potentially also *in vivo* estimates of the dissociation rate constant.

## Acknowledgements

This research was supported by grants from the National Institutes of Health (R21NS090169, K99DA037928, R90DA023427, P41EB015896, S10RR026666, S10RR022976, S10RR019933, S10RR017208) and the Danish Innovation Foundation through the Center for Experimental Medicine Neuropharmacology at the University of Copenhagen and Rigshospitalet. The authors declare no conflict of interest.

## Appendix

The first-order differential equations that define the FRTM model in Fig. 1a are:

$$\begin{aligned} \dot{C}_R &= K_1' C_P - k_2' C_R \\ \dot{C}_F &= K_1 C_P - k_2 C_F - k_3 C_F + k_4 C_B \\ \dot{C}_B &= k_3 C_F - k_4 C_B \\ C_T &= C_F + C_B \end{aligned} \quad [\text{A1}]$$

If  $R_f$  is defined as the ratio  $K_1/K_1'$  and the distribution volume of non-specifically bound tracer is equal in all tissues ( $K_1/K_1' = k_2/k_2'$ ), then the plasma concentration can be

eliminated to produce an equation for the target tissue that depends upon the reference region and either the free or bound concentrations:

$$\dot{C}_T = R_1 \dot{C}_R + k_2 C_R - k_2 (C_T - C_B) \quad [\text{A2}]$$

The bound concentration in this equation is not directly measurable. SRTM (Fig. 1b) addresses this problem by positing fast exchange within the target tissue to produce a “1-tissue model” (Lammertsma and Hume, 1996). As an alternative to the SRTM approximation, one can solve the time dependence of the bound compartment. Eq. A1 provides the differential equation for the bound concentration, and the solution is subject to the initial condition that tissues are devoid of specifically bound PET radioligand at time zero.

$$\begin{aligned} \dot{C}_B &= - (k_3 + k_4) C_B + k_3 C_T \\ C_B &= k_3 e^{-(k_3 + k_4)t} \int_0^t e^{(k_3 + k_4)t'} C_T(t') dt' \end{aligned} \quad [\text{A3}]$$

A more convenient expression can be obtained using integration by parts to write the solution of Eq. A3 in terms of the tissue concentration and derivative, while also defining  $BP_{ND} = k_3/k_4$  and using notation of a convolution integral ( $\otimes$ ):

$$\begin{aligned} C_B &= k_3 e^{-(k_3 + k_4)t} \int_0^t C_T e^{(k_3 + k_4)t'} dt' = k_3 e^{-(k_3 + k_4)t} \left[ \frac{e^{(k_3 + k_4)t}}{k_3 + k_4} C_T - \int_0^t \dot{C}_T \frac{e^{(k_3 + k_4)t'}}{k_3 + k_4} dt' \right] \\ &= \frac{BP_{ND}}{(1 + BP_{ND})} \left[ C_T - \dot{C}_T \otimes e^{-k_4(1 + BP_{ND})t} \right] \end{aligned} \quad [\text{A4}]$$

Eq. A4 can be substituted into Eq. A2 to write a reference tissue model that no longer depends upon explicitly upon the bound concentration:

$$\begin{aligned} \dot{C}_T &= R_1 \dot{C}_R + k_2 C_R - k_2 C_T + k_2 \left( 1 - \frac{1}{1 + BP_{ND}} \right) \left[ C_T - \dot{C}_T \otimes e^{-k_4(1 + BP_{ND})t} \right] \\ &= R_1 \dot{C}_R + k_2 \left( C_R - \dot{C}_T \otimes e^{-k_4(1 + BP_{ND})t} \right) - \frac{k_2}{1 + BP_{ND}} \left( C_T - \dot{C}_T \otimes e^{-k_4(1 + BP_{ND})t} \right) \end{aligned}$$

[A5]

We can employ the same definition for  $k_{2a} (= k_2 / (1 + BP_{ND}))$  used in SRTM (Lammertsma and Hume, 1996) and integrate both sides of Eq. A5 to produce a form for FRTM that mimics common representations of SRTM.

$$C_T = R_1 C_R + k_2 \int \left( C_R - \dot{C}_T \otimes e^{-k_4(1 + BP_{ND})t} \right) - k_{2a} \int \left( C_T - \dot{C}_T \otimes e^{-k_4(1 + BP_{ND})t} \right) \quad [\text{A6}]$$

Note that Eq. A6 becomes SRTM in the fast-exchange limit when the rate constants  $k_3$  and  $k_4$  approach infinity, or when the tissue concentration maintains a true steady state, for then the convolution terms disappear. Computation of  $BP_{ND}$  is performed identically for SRTM or rFRTM:  $BP_{ND} = k_2 / k_{2a} - 1$ .


## Literature

- Alpert NM, Badgaiyan RD, Livni E, Fischman AJ. A novel method for noninvasive detection of neuromodulatory changes in specific neurotransmitter systems. *Neuroimage*. 2003; 19:1049–1060. [PubMed: 12880831]
- Chugani DC, Ackermann RF, Phelps ME. In vivo [ $^3\text{H}$ ]spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization. *J Cereb Blood Flow Metab*. 1988; 8:291–303. [PubMed: 2966803]
- Cropley VL, Innis RB, Nathan PJ, Brown AK, Sangare JL, Lerner A, Ryu YH, Sprague KE, Pike VW, Fujita M. Small effect of dopamine release and no effect of dopamine depletion on [ $^{18}\text{F}$ ]fallypride binding in healthy humans. *Synapse*. 2008; 62:399–408. [PubMed: 18361438]
- Cunningham VJ, Hume SP, Price GR, Ahier RG, Cremer JE, Jones AK. Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equilibrium data in vitro. *J Cereb Blood Flow Metab*. 1991; 11:1–9. [PubMed: 1845764]
- Farde L, Eriksson L, Blomquist G, Halldin C. Kinetic analysis of central [ $^{11}\text{C}$ ]raclopride binding to D2- dopamine receptors studied by PET—a comparison to the equilibrium analysis. *J Cereb Blood Flow Metab*. 1989; 9:696–708. [PubMed: 2528555]
- Ginovart N. Imaging the dopamine system with in vivo [ $^{11}\text{C}$ ]raclopride displacement studies: understanding the true mechanism. *Mol Imaging Biol*. 2005; 7:45–52. [PubMed: 15912275]
- Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. *J Cereb Blood Flow Metab*. 2001; 21:635–652. [PubMed: 11488533]
- Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. *Neuroimage*. 1997; 6:279–287. [PubMed: 9417971]
- Hakyemez HS, Dagher A, Smith SD, Zald DH. Striatal dopamine transmission in healthy humans during a passive monetary reward task. *Neuroimage*. 2008; 39:2058–2065. [PubMed: 18063390]
- Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, Suhara T, Suzuki K, Innis RB, Carson RE. Linearized reference tissue parametric imaging methods: application to [ $^{11}\text{C}$ ]DASB positron emission tomography studies of the serotonin transporter in human brain. *J Cereb Blood Flow Metab*. 2003; 23:1096–1112. [PubMed: 12973026]
- Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RS. Comparison of methods for analysis of clinical [ $^{11}\text{C}$ ]raclopride studies. *J Cereb Blood Flow Metab*. 1996; 16:42–52. [PubMed: 8530554]
- Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. *Neuroimage*. 1996; 4:153–158. [PubMed: 9345505]
- Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. *J Cereb Blood Flow Metab*. 2000; 20:423–451. [PubMed: 10724107]
- Lee DE, Gallezot JD, Zheng MQ, Lim K, Ding YS, Huang Y, Carson RE, Morris ED, Cosgrove KP. Test-retest reproducibility of [ $^{11}\text{C}$ ]-(+)-propyl-hexahydro-naphtho-oxazin positron emission tomography using the bolus plus constant infusion paradigm. *Mol Imaging*. 2013; 12:77–82. [PubMed: 23415395]
- Logan J, Fowler JS, Volkow ND, Ding YS, Wang GJ, Alexoff DL. A strategy for removing the bias in the graphical analysis method. *J Cereb Blood Flow Metab*. 2001; 21:307–320. [PubMed: 11295885]
- Mandeville JB, Sander CY, Jenkins BG, Hooker JM, Catana C, Vanduffel W, Alpert NM, Rosen BR, Normandin MD. A receptor-based model for dopamine-induced fMRI signal. *Neuroimage*. 2013; 75:46–57. [PubMed: 23466936]




- Martin-Soelch C, Szczepanik J, Nugent A, Barhaghi K, Rallis D, Herscovitch P, Carson RE, Drevets WC. Lateralization and gender differences in the dopaminergic response to unpredictable reward in the human ventral striatum. *Eur J Neurosci*. 2011; 33:1706–1715. [PubMed: 21453423]
- Muzic RF Jr, Christian BT. Evaluation of objective functions for estimation of kinetic parameters. *Medical physics*. 2006; 33:342–353. [PubMed: 16532939]
- Normandin MD, Schiffer WK, Morris ED. A linear model for estimation of neurotransmitter response profiles from dynamic PET data. *Neuroimage*. 2012; 59:2689–2699. [PubMed: 21767654]
- Pappata S, Dehaene S, Poline JB, Gregoire MC, Jobert A, Delforge J, Frouin V, Bottlaender M, Dolle F, Di Giambardino L, Syrota A. In vivo detection of striatal dopamine release during reward: a PET study with [(11)C]raclopride and a single dynamic scan approach. *Neuroimage*. 2002; 16:1015–1027. [PubMed: 12202089]
- Rohlfing T, Kroenke CD, Sullivan EV, Dubach MF, Bowden DM, Grant KA, Pfefferbaum A. The INIA19 Template and NeuroMaps Atlas for Primate Brain Image Parcellation and Spatial Normalization. *Frontiers in neuroinformatics*. 2012; 6:27. [PubMed: 23230398]
- Salinas CA, Searle GE, Gunn RN. The simplified reference tissue model: model assumption violations and their impact on binding potential. *J Cereb Blood Flow Metab*. 2015; 35:304–311. [PubMed: 25425078]
- Sander CY, Hooker JM, Catana C, Normandin MD, Alpert NM, Knudsen GM, Vanduffel W, Rosen BR, Mandeville JB. Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. *Proc Natl Acad Sci U S A*. 2013; 110:11169–11174. [PubMed: 23723346]
- Sander CY, Hooker JM, Catana C, Rosen BR, Mandeville JB. Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI. *Neuropsychopharmacology*. 2015
- Sander CY, Hooker JM, Wey HY, Catana C, Rosen BR, Mandeville JB. Effects of simultaneously measured flow changes on D2/D3 radiotracer dynamics. *Neuroreceptor Mapping*, pp O-016 Amsterdam. 2014
- Schuitmaker A, van Berckel BN, Kropholler MA, Kloet RW, Jonker C, Scheltens P, Lammertsma AA, Boellaard R. Evaluation of methods for generating parametric (R-[11C]PK11195 binding images. *J Cereb Blood Flow Metab*. 2007; 27:1603–1615. [PubMed: 17311080]
- Seneca N, Gulyas B, Varrone A, Schou M, Airaksinen A, Tauscher J, Vandenhende F, Kielbasa W, Farde L, Innis RB, Halldin C. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2. *Psychopharmacology (Berl)*. 2006; 188:119–127. [PubMed: 16896954]
- Seo S, Kim SJ, Kim YK, Lee JY, Jeong JM, Lee DS, Lee JS. Comparative assessment of parametric neuroreceptor mapping approaches based on the simplified reference tissue model using [C]ABP688 PET. *J Cereb Blood Flow Metab*. 2015
- Slifstein M, Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. *Nucl Med Biol*. 2001; 28:595–608. [PubMed: 11516703]
- Slifstein M, Parsey RV, Laruelle M. Derivation of [(11)C]WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions. *Nucl Med Biol*. 2000; 27:487–492. [PubMed: 10962256]
- Thiele F, Buchert R. Evaluation of non-uniform weighting in non-linear regression for pharmacokinetic neuroreceptor modelling. *Nuclear medicine communications*. 2008; 29:179–188. [PubMed: 18094641]
- Varnas K, Nyberg S, Halldin C, Varrone A, Takano A, Karlsson P, Andersson J, McCarthy D, Smith M, Pierson ME, Soderstrom J, Farde L. Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. *J Cereb Blood Flow Metab*. 2011; 31:113–123. [PubMed: 20424633]
- Vernaleken I, Peters L, Raptis M, Lin R, Buchholz HG, Zhou Y, Winz O, Rosch F, Bartenstein P, Wong DF, Schafer WM, Grunder G. The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations. *J Cereb Blood Flow Metab*. 2011; 31:1958–1966. [PubMed: 21587267]
- Wooten D, Christopoulos A, Sexton PM. Emerging paradigms in GPCR allosterity: implications for drug discovery. *Nature reviews Drug discovery*. 2013; 12:630–644. [PubMed: 23903222]

- Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. *J Cereb Blood Flow Metab.* 2002; 22:1440–1452. [PubMed: 12468889]
- Zald DH, Boileau I, El-Dearedy W, Gunn R, McGlone F, Dichter GS, Dagher A. Dopamine transmission in the human striatum during monetary reward tasks. *J Neurosci.* 2004; 24:4105–4112. [PubMed: 15115805]
- Zhou Y, Chen MK, Endres CJ, Ye W, Brasic JR, Alexander M, Crabb AH, Guilarte TR, Wong DF. An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. *Neuroimage.* 2006; 33:550–563. [PubMed: 16920365]


**Fig. 1.**

The full reference tissue model (a) and simplified reference tissue model (b) use a single compartment to describe the concentration of PET radioligand in the reference region ( $C_R$ ) so that the plasma concentration ( $C_P$ ) is not needed in analysis. FRTM partitions other tissue concentrations into free ( $C_F$ ) and specifically bound ( $C_B$ ) fractions, whereas SRTM assumes fast exchange between these compartments and thus approximates all tissues using a single compartment model.




**Fig. 2.**

a) Simulated time-activities of a reference region (gray) and target region (black) for relatively low-binding regions using (a)  $BP = 1$  and  $1/k_4 = 15$  min. b) The corresponding ratio of bound to total concentration of PET ligand in the target region versus time (black points) is compared to the model estimate for SRTM (red) and FRTM using values of  $1/k_4$  from 5 to 25 minutes.




**Fig. 3.**

Analyses of simulated data. (a) An offset time constant  $1/k_4$  equal to the true value (15 min) removes the variation of the derived reference-region outflow time constant  $1/k'_2$  versus BP using rFRTM. A value of  $1/k_4=0$  corresponds to SRTM (red). (b) Bias in  $BP_{ND}$  for the same set of  $k_4$  values used in panel (a). (c) Bias in  $BP_{ND}$  for 2-parameter reductions SRTM2 (red) and rFRTM2 (black) using values for  $1/k'_2$  of 16.5 min (long dashes) or 17 min (short dashes). (d) The percent standard deviation of  $BP_{ND}$  values at varying levels of noise.




**Fig 4.**

a) Noiseless simulations of [11C]raclopride bias in occupancy for SRTM, SRTM2 using two different values of  $k_2'$  (see text), and rFRTM2 as calibrated using Eq. 3. b) A typical TAC for simulations of a localized 10% increase in occupancy occurring at 40 minutes in the right nucleus accumbens (cyan); the image shows basal  $BP_{ND}$  values used in simulations. c) Maps of change in  $BP_{ND}$  using different analysis methods; clockwise from top left: SRTM, SRTM2, SRTM2 using a BI infusion, and rFRTM2.



**Fig. 5.** Data obtained in isoflurane-anesthetized NHP using different PET radioligands. Fitting the  $BP_{ND}$  functionality of the reference region washout time constant ( $1/k_2'$ ) for different values of the dissociation time constant ( $1/k_4$ ) facilitated model identification using Eq. 3. Red data points correspond to SRTM analysis ( $1/k_4=0$ ), and other sets of data points used analysis values of  $1/k_4$  that were progressively stepped by either 3 min (a-c) or 15 min (d).



**Fig. 6.**

a) A time-activity curve for  $[^{11}\text{C}]\text{NNC-112}$  from a single voxel in putamen (black) and the rFRTM correction term of Eq. 2 (blue). b) Whole putamen (gray dots) together with an SRTM fit (gray solid line) and the reference-region (cerebellum) scaled by  $R_1$  (gray dashes); the corresponding black points and curves are the rFRTM modified data (Eq. 2), the rFRTM fit, and the  $R_1$  contribution. c) A map of  $BP_{ND}$  produced by rFRTM2 analysis of  $[^{11}\text{C}]\text{NNC-112}$  in NHP. d) The percent difference of  $BP_{ND}$  values produced by SRTM2 relative to rFRTM2, with blue-green colors indicating smaller SRTM2 values and red-yellow colors indicating larger SRTM2 values.



**Table 1**

Parameters used in simulations

Fig.	K1' (ml/ml/min)	1/k2' (min)	1/k4 (min)	k <sub>3</sub> /k <sub>4</sub> (BP)	R1	Noise Model
2	0.05	16.5	15	1	0.85	None
3a-c	0.05	16.5	15	Variable	0.85	None
3d	0.05	16.5	15	1	0.85	(**)
4	0.15	3.5	10	(*)	(*)	(**)

(\*) Spatial distribution measured across NHP basal ganglia.

(\*\*) Noise followed a standard model (Logan et al., 2001).